Polyclonal Antibody to Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4)
Code | Size | Price |
---|
PAB519Ra01-20ul | 20ul | £88.00 |
Quantity:
PAB519Ra01-100ul | 100ul | £165.00 |
Quantity:
PAB519Ra01-200ul | 200ul | £223.00 |
Quantity:
PAB519Ra01-1ml | 1ml | £512.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD134; TNFRSF4; ACT35; OX40; TXGP1L; TAX transcriptionally-activated glycoprotein 1 receptor
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Immunogen:
RPB519Ra01-Recombinant Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4)
Item Name:
Tumor Necrosis Factor Receptor Superfamily, Member 4
Source:
Polyclonal antibody preparation
Subcategory:
Polyclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4) | RPB519Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||